Skip to Main Content

An experimental pill from Viking Therapeutics (VKTX) reduced liver fat in patients with early signs of fatty liver disease, according to results from a mid-stage clinical trial announced Tuesday.

The promising clinical trial results thrust Viking into the mix of companies racing to develop new treatments for NASH, the commonly used acronym for non-alcoholic steatohepatitis, a chronic disease in which fat accumulates in the liver.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED